




RealRate

PHARMACEUTICAL 2022

Immunix INC
Rank 169 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Immunic INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunic INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Immunic INC is the variable Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 58% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	104,988
Cost of Goods Sold	0
Intangible Assets	32,970
Liabilities, Current	11,401
Liabilities, Non-Current	584
Other Assets	990
Other Compr. Net Income	3,860
Other Expenses	17,250
Other Liabilities	0
Other Net Income	-1,280
Other Revenues	0
Property and Equipment	152
Research and Development	61,115
Selling, General and Administrative Expense	13,300

Output Variable	Value in 1000 USD
Assets	139,100
Liabilities	11,985
Expenses	91,665
Revenues	0
Stockholders Equity	127,115
Net Income	-92,945
Comprehensive Net Income	-91,015
BaseVar	123,945
ECR before LimitedLiability	246%
Economic Capital Ratio	333%